103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB4411

 

Introduced 1/16/2024, by Rep. Dave Vella

 

SYNOPSIS AS INTRODUCED:
 
225 ILCS 85/19.1

    Amends the Pharmacy Practice Act. Provides that a pharmacist must ensure that a sign warning of the dangers associated with opioids is conspicuously displayed in the pharmacy. Provides that the Department of Public Health shall develop the form and content of the sign.


LRB103 36081 RPS 66170 b

 

 

A BILL FOR

 

HB4411LRB103 36081 RPS 66170 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Pharmacy Practice Act is amended by
5changing Section 19.1 as follows:
 
6    (225 ILCS 85/19.1)
7    (Section scheduled to be repealed on January 1, 2028)
8    Sec. 19.1. Dispensing opioids and opioid antagonists.
9    (a) Due to the recent rise in opioid-related deaths in
10Illinois and the existence of an opioid antagonist that can
11reverse the deadly effects of overdose, the General Assembly
12finds that in order to avoid further loss where possible, it is
13responsible to allow greater access of such an antagonist to
14those populations at risk of overdose.
15    (b) Notwithstanding any general or special law to the
16contrary, a licensed pharmacist shall dispense an opioid
17antagonist in accordance with written, standardized procedures
18or protocols developed by the Department with the Department
19of Public Health and the Department of Human Services and
20filed at the pharmacy before implementation and are available
21to the Department upon request.
22    (c) Before dispensing an opioid, a pharmacist shall inform
23patients that opioids are addictive and offer to dispense an

 

 

HB4411- 2 -LRB103 36081 RPS 66170 b

1opioid antagonist. A pharmacist must ensure that a sign
2warning of the dangers associated with opioids is
3conspicuously displayed in the pharmacy. The Department of
4Public Health shall develop the form and content of the sign.
5    (d) For the purpose of this Section, "opioid antagonist"
6means a drug that binds to opioid receptors and blocks or
7inhibits the effect of opioids acting on those receptors,
8including, but not limited to, naloxone hydrochloride or any
9other similarly acting and equally safe drug approved by the
10U.S. Food and Drug Administration for the treatment of drug
11overdose.
12(Source: P.A. 102-1040, eff. 1-1-23.)